2,334
Views
3
CrossRef citations to date
0
Altmetric
Original Research Article

Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)

, , , , , , , , , , & show all
Pages 393-399 | Received 20 Jul 2018, Accepted 23 Oct 2018, Published online: 22 Nov 2018

References

  • Egarter C, Frey Tirri B, Bitzer J, et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Women’s Health. 2013;13.
  • Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception. 2011;84:19–34.
  • Chabbert-Buffet N, Gerris J, Jamin C, et al. Toward a new concept of ‘natural balance’ in oral estroprogestin contraception. Gynecol Endocrinol. 2013;29:891–896.
  • Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16:430–443.
  • Westhoff C, Kaunitz AM, Korver T, et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial. Obstet Gynecol. 2012;119:989–999.
  • Witjes H, Creinin MD, Sundstrom-Poromaa I, et al. Comparative analysis of the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care. 2015;20:296–307.
  • Grandi G, Napolitano A, Xholli A, et al. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea. Gynecol Endocrinol. 2015;31:774–778.
  • Lete I, de la Viuda E, Perez-Campos E, et al. Effect on quality of life of switching to combined oral contraception based on natural estrogen: an observational, multicentre, prospective phase IV study (ZOCAL Study). Eur J Contracept Reprod Health Care. 2016;21:276–284.
  • European Medicines Agency. Zoely 2.5 mg/1.5 mg film-coated tablets. Summary of product characteristics; 2016 [accessed 2016 May 17]. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/0012 13/WC500115831.pdf.
  • Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. Eur J Contracept Reprod Health Care. 2015;20:329–343.
  • Huber LR, Hogue CJ, Stein AD, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. Am J Obstet Gynecol. 2006;194:1290–1295.
  • Wigginton B, Harris ML, Loxton D, et al. A qualitative analysis of women’s explanations for changing contraception: the importance of non-contraceptive effects. J Fam Plann Reprod Health Care. 2016;42:256–262.
  • Lete I, Barbadillo N, Ugarte L, et al. A cross-sectional study of the choice of oral estrogen contraceptives in women seeking contraceptive counseling: what type of pill do women prefer after being counseled? Gynecol Obstet. 2015;5:100321.
  • Caruso S, Cianci S, Cariola M, et al. Improvement of low sexual desire due to antiandrogenic combined oral contraceptives after switching to an oral contraceptive containing 17β-estradiol. J Women’s Health (Larchmt). 2017;26:728–734.
  • Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig. 2010;30:749–763.
  • Johnson S, Pion C, Jennings V. Current methods and attitudes of women towards contraception in Europe and America. Reprod Health 2013;10.
  • Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76:267–272.
  • Lete I, Perez-Campos E, Correa M, et al. Continuation rate of combined hormonal contraception: a prospective multicenter study. J Women’s Health (Larchmt). 2012;21:490–495.
  • Moreau C, Bouyer J, Bajos N, et al. Frequency of discontinuation of contraceptive use: results from a French population-based cohort. Hum Reprod. 2009;24:1387–1392.
  • Van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;11:CD003553.
  • Murphy PA, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception. 2008;77:257–263.